NCT00687414

Brief Summary

Aim of the study is to analyze the expression of genes and sequences encoding the human mammalian diaphanous (mDia) related formin proteins to test the hypothesis that defects in the mDia expression or function might drive the pathophysiology of myelodysplastic syndrome, acute myeloid leukemia and other myeloproliferative diseases.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2008

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2008

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 27, 2008

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 30, 2008

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2010

Completed
Last Updated

July 27, 2023

Status Verified

July 1, 2023

Enrollment Period

1.7 years

First QC Date

May 27, 2008

Last Update Submit

July 26, 2023

Conditions

Myeloproliferative DisorderMDSAML

Keywords

gene expressiongene sequencinggene encodingMPDMDSAMLmDia

Outcome Measures

Primary Outcomes (1)

  • to determine if defective DRF1 expression or mDia1 function may contribute to myeloid malignancies and point to mDia1 as an attractive therapeutic target in MDS and MPS

    within a year

Study Arms (2)

adults

male and female with MDS and MPD and AML

Healthy

Healthy control group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Community sample

You may qualify if:

  • and over
  • Male
  • Female
  • Diagnosed with MDS, MPD and AML

You may not qualify if:

  • Under the age of 18
  • Received bone marrow transplant
  • Control Group Criteria:
  • healthy men and women
  • ≥ 55 years of age
  • history of hematological condition
  • history of cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

St Mary's Health Care

Grand Rapids, Michigan, 49503, United States

Location

Van Andel Research Institute

Grand Rapids, Michigan, 49503, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

peripheral blood

MeSH Terms

Conditions

Myeloproliferative Disorders

Condition Hierarchy (Ancestors)

Bone Marrow DiseasesHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Arthur S Alberts, PhD

    Van Andel Research Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 27, 2008

First Posted

May 30, 2008

Study Start

April 1, 2008

Primary Completion

December 1, 2009

Study Completion

January 1, 2010

Last Updated

July 27, 2023

Record last verified: 2023-07

Locations

US(2)